DK1027053T3 - Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser - Google Patents

Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser

Info

Publication number
DK1027053T3
DK1027053T3 DK98952186T DK98952186T DK1027053T3 DK 1027053 T3 DK1027053 T3 DK 1027053T3 DK 98952186 T DK98952186 T DK 98952186T DK 98952186 T DK98952186 T DK 98952186T DK 1027053 T3 DK1027053 T3 DK 1027053T3
Authority
DK
Denmark
Prior art keywords
administration
patient
cyclosporin
tacrolimus
pps
Prior art date
Application number
DK98952186T
Other languages
English (en)
Inventor
Gary E Striker
Lilliane Striker
Kenneth H Kortright
Original Assignee
Ivax Research Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ivax Research Inc, Us Health filed Critical Ivax Research Inc
Application granted granted Critical
Publication of DK1027053T3 publication Critical patent/DK1027053T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Cephalosporin Compounds (AREA)
DK98952186T 1997-10-09 1998-10-09 Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser DK1027053T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6294797P 1997-10-09 1997-10-09

Publications (1)

Publication Number Publication Date
DK1027053T3 true DK1027053T3 (da) 2004-09-06

Family

ID=22045901

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98952186T DK1027053T3 (da) 1997-10-09 1998-10-09 Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser

Country Status (24)

Country Link
US (1) US6187745B1 (da)
EP (1) EP1027053B1 (da)
JP (1) JP2001519392A (da)
KR (1) KR100515196B1 (da)
CN (1) CN1154492C (da)
AT (1) ATE269098T1 (da)
AU (1) AU748495B2 (da)
BR (1) BR9813860A (da)
CA (1) CA2304374A1 (da)
CZ (1) CZ297440B6 (da)
DE (1) DE69824619T2 (da)
DK (1) DK1027053T3 (da)
ES (1) ES2221714T3 (da)
HK (1) HK1026845A1 (da)
HU (1) HUP0003904A3 (da)
IL (1) IL135235A0 (da)
NO (1) NO20001828L (da)
NZ (1) NZ503493A (da)
PL (1) PL191993B1 (da)
PT (1) PT1027053E (da)
RU (1) RU2191020C2 (da)
SK (1) SK285332B6 (da)
UA (1) UA65587C2 (da)
WO (1) WO1999018961A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR035026A1 (es) 2000-01-19 2004-04-14 Baker Norton Pharma Uso de pentosan polisulfato en el tratamiento de ciertas condiciones de la prostata
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
CN1274294C (zh) * 2001-10-19 2006-09-13 伊索泰克尼卡股份有限公司 环孢菌素类似物微乳液预浓缩物
KR20040101381A (ko) * 2002-04-16 2004-12-02 후지사와 야꾸힝 고교 가부시키가이샤 신규한 용도
EP2165711B1 (en) 2004-05-27 2014-05-21 Baxter International Inc. Methods for treating bleeding disorders using sulfated polysaccharides
EP2326334A2 (en) 2008-08-22 2011-06-01 Baxter Healthcare SA Methods for treating bleeding disorders
US8632991B2 (en) 2010-01-14 2014-01-21 Baxter International Inc. Methods and compositions for treating bleeding disorders
WO2011088418A2 (en) * 2010-01-15 2011-07-21 Mount Sinai School Of Medicine Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate
CN102327282A (zh) * 2010-09-01 2012-01-25 吴洪 戊糖多聚硫酸酯用于制备治疗糖尿病肾病的药物中的用途
DK2734213T3 (da) 2011-07-19 2018-08-13 Baxalta GmbH Resorptionsfremmere som additiver til at forbedre den orale formulering af ikke-antikoagulerende sulfatholdige polysaccharider
KR20140097152A (ko) 2011-10-05 2014-08-06 알러간, 인코포레이티드 손발톱 건강을 증진하기 위한 조성물
ES2737025T3 (es) 2012-08-14 2020-01-09 Baxalta GmbH Métodos y sistemas para el cribado de composiciones que comprenden polisacáridos sulfados no anticoagulantes
KR101760510B1 (ko) 2014-12-18 2017-07-21 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
WO2016099214A1 (ko) * 2014-12-18 2016-06-23 가톨릭대학교 산학협력단 메트포민을 포함하는 면역억제제로 인한 신장 독성 완화용 조성물 및 이를 포함하는 면역질환 예방 또는 치료용 조성물
RU2680098C1 (ru) * 2015-06-12 2019-02-15 Вишал Джаджодиа Свати Лекарственное средство, содержащее пентозанполисульфат натрия, для использования в лечении обструкции выходного отверстия мочевого пузыря и/или симптомов нижних мочевых путей

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0466315A3 (en) 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5204329A (en) 1990-06-11 1993-04-20 Du Pont Merck Pharmaceutical Company Treatment of organ transplantation rejection
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
IT1277147B1 (it) * 1995-01-20 1997-11-04 Sigma Tau Ind Farmaceuti Uso della carnitina e i suoi derivati per ridurre gli effetti tossici della ciclosporina-a e di altri farmaci immunosoppressivi.
JPH08208489A (ja) * 1995-02-03 1996-08-13 L T T Kenkyusho:Kk 腎不全治療剤
US5643892A (en) * 1995-06-07 1997-07-01 Baker Norton Pharmaceuticals, Inc. Method of treating chronic progressive vascular diseases

Also Published As

Publication number Publication date
NO20001828D0 (no) 2000-04-07
NZ503493A (en) 2001-11-30
HK1026845A1 (en) 2000-12-29
CZ20001274A3 (cs) 2001-12-12
CN1275080A (zh) 2000-11-29
UA65587C2 (en) 2004-04-15
IL135235A0 (en) 2001-05-20
CZ297440B6 (cs) 2006-12-13
PL191993B1 (pl) 2006-08-31
NO20001828L (no) 2000-05-15
HUP0003904A1 (hu) 2001-08-28
BR9813860A (pt) 2001-03-20
CA2304374A1 (en) 1999-04-22
EP1027053B1 (en) 2004-06-16
EP1027053A1 (en) 2000-08-16
AU9794398A (en) 1999-05-03
HUP0003904A3 (en) 2006-06-28
ATE269098T1 (de) 2004-07-15
SK285332B6 (sk) 2006-11-03
EP1027053A4 (en) 2002-05-22
AU748495B2 (en) 2002-06-06
CN1154492C (zh) 2004-06-23
PT1027053E (pt) 2004-09-30
WO1999018961A1 (en) 1999-04-22
US6187745B1 (en) 2001-02-13
DE69824619T2 (de) 2005-06-23
PL339774A1 (en) 2001-01-02
KR100515196B1 (ko) 2005-09-16
JP2001519392A (ja) 2001-10-23
RU2191020C2 (ru) 2002-10-20
ES2221714T3 (es) 2005-01-01
SK4672000A3 (en) 2001-09-11
DE69824619D1 (de) 2004-07-22
KR20010030749A (ko) 2001-04-16

Similar Documents

Publication Publication Date Title
DK1027053T3 (da) Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
ES2188782T3 (es) Formulaciones farmaceuticas que contienen darifenacina.
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CO5261582A1 (es) Composiciones de valdecoxib
KR950031069A (ko) 골손실의 억제 및 혈청 콜레스테롤의 강하 방법
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
JP2002523370A5 (da)
KR910019618A (ko) 발기부전증 치료용 제약 조성물
CA2277365A1 (en) Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
KR19980701720A (ko) 세스키테르펜 락톤 및 비타민 b 복합체를 함유하는 편두통 및 기타 질환 치료용 복합약
MY124465A (en) Reduction of infarct volume using citicoline
CA2537748A1 (en) Use of telmisartan for the prevention of vascular headache
KR900011461A (ko) 트립스타틴을 유효성분으로 하는 치료제
EP0190851B1 (en) Improved antiinflammatory composition
NO974486L (no) Lavdoserte "Ridogrel"-formuleringer samt anvendelse derav ved behandling av tarmbetennelse
BE1002255A5 (fr) Medicaments.
BE1002256A3 (fr) Medicaments.
ATE91890T1 (de) Herstellung eines arzneimittels gegen arthritis und rheumatismus.
NZ315632A (en) Process for preparing solid dosage forms of very low-dose drugs comprising admixing 1-3% by weight of carrier particles with a solution of drug in water
KR830008678A (ko) 진통 조성물
KR890701111A (ko) 사람의 이상지혈증의 치료방법
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
JPH0296521A (ja) 免疫性疾患治療剤